Overview

Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design

Status:
Recruiting

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design

Phase:

Phase 2

Details

Lead Sponsor:

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborator:

AstraZeneca

Treatments:

Durvalumab
Tremelimumab